Better Buy: CRISPR Therapeutics Vs. Viking Therapeutics
CRISPR Therapeutics (NASDAQ: CRSP) and Viking Therapeutics (NASDAQ: VKTX) are among the hottest mid-cap biotechs on the market. Both have delivered incredible progress in recent months, be it on the clinical or regulatory front. These relatively small drugmakers look highly promising thanks to their incredible, innovative potential.
That's why investors keep bidding up their shares -- although Viking has been the better performer of the two, by a mile, over the past year. So which one of these two stocks will outperform the other over the long run? Let's find out.
Source Fool.com
Viking Therapeutics Inc Aktie
56,72 €
2,68 %
Viking Therapeutics Inc erfreut sich mäßiger Beliebtheit, mit mehr Buy- als Sell-Einschätzungen.
Für Viking Therapeutics Inc ergibt sich mit einem Kursziel von 110 € eine mögliche Steigerung von über 50% gegenüber 56.72 €.
